Display options
Cite
Rodeles LM, Peverengo LM, Benítez R, et al. Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina. Rev Panam Salud Publica. 2021;45:e66doi: 10.26633/RPSP.2021.66.
Rodeles, L. M., Peverengo, L. M., Benítez, R., Benzaquen, N., Serravalle, P., Long, A. K., Ferreira, V., Benitez, A. D., Zunino, L., Lizarraga, C., & Vicco, M. H. (2021). Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina. Revista panamericana de salud publica = Pan American journal of public health, 45e66. https://doi.org/10.26633/RPSP.2021.66
Rodeles, Luz María, et al. "Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina." Revista panamericana de salud publica = Pan American journal of public health vol. 45 (2021): e66. doi: https://doi.org/10.26633/RPSP.2021.66
Rodeles LM, Peverengo LM, Benítez R, Benzaquen N, Serravalle P, Long AK, Ferreira V, Benitez AD, Zunino L, Lizarraga C, Vicco MH. Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina. Rev Panam Salud Publica. 2021 Jun 21;45:e66. doi: 10.26633/RPSP.2021.66. eCollection 2021. PMID: 34168682; PMCID: PMC8216497.
Copy Download .nbib Format: NLM
Share it on

Rev Panam Salud Publica. 2021 Jun 21;45:e66. doi: 10.26633/RPSP.2021.66. eCollection 2021.

Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.

Revista panamericana de salud publica = Pan American journal of public health

Luz María Rodeles, Luz María Peverengo, Romina Benítez, Nadia Benzaquen, Priscila Serravalle, Ana Karina Long, Virginia Ferreira, Agostina Daiana Benitez, Luisina Zunino, Camila Lizarraga, Miguel Hernán Vicco

Affiliations

  1. Universidad Nacional del Litoral Santa Fe Argentina Universidad Nacional del Litoral, Santa Fe, Argentina.
  2. Centro de Especialidades Médicas Santa Fe Argentina Centro de Especialidades Médicas, Santa Fe, Argentina.
  3. Sanatorio Diagnóstico Santa Fe Argentina Sanatorio Diagnóstico, Santa Fe, Argentina.

PMID: 34168682 PMCID: PMC8216497 DOI: 10.26633/RPSP.2021.66

Abstract

OBJECTIVE: To evaluate the seroprevalence of COVID-19 infection in pauci-symptomatic and asymptomatic people, the associated epidemiological factors, and IgG antibody kinetic over a 5-month period to get a better knowledge of the disease transmissibility and the rate of susceptible persons that might be infected.

METHODS: Seroprevalence was evaluated by a cross-sectional study based on the general population of Santa Fe, Argentina (non-probabilistic sample) carried out between July and November 2020. A subgroup of 20 seropositive individuals was followed-up to analyze IgG persistence. For the IgG anti-SARS-CoV-2 antibodies detection, the COVID-AR IgG

RESULTS: 3 000 individuals were included conforming asymptomatic and pauci-symptomatic groups (n=1 500 each). From the total sample, only 8.83% (n=265) presented reactivity for IgG anti-SARS-CoV-2. A significant association was observed between positive anti-SARS-CoV-2 IgG and a history of contact with a confirmed case; the transmission rate within households was approximately 30%. In the pauci-symptomatic group, among the seropositive ones, anosmia and fever presented an OR of 16.8 (95% CI 9.5-29.8) and 2.7 (95% CI 1.6-4.6), respectively (p <0.001). In asymptomatic patients, IgG levels were lower compared to pauci-symptomatic patients, tending to decline after 4 months since the symptoms onset.

CONCLUSION: We observed a low seroprevalence, suggestive of a large population susceptible to the infection. Anosmia and fever were independent significant predictors for seropositivity. Asymptomatic patients showed lower levels of antibodies during the 5-month follow-up. IgG antibodies tended to decrease over the end of this period regardless of symptoms.

Keywords: Argentina; SARS-CoV-2; Seroprevalence; anosmia; asymptomatic diseases; epidemiology

References

  1. N Engl J Med. 2020 Jun 11;382(24):2302-2315 - PubMed
  2. Nat Med. 2020 Aug;26(8):1200-1204 - PubMed
  3. Ann Intern Med. 2020 Sep 1;173(5):362-367 - PubMed
  4. Science. 2020 Dec 4;370(6521):1227-1230 - PubMed
  5. J Infect. 2020 Dec;81(6):931-936 - PubMed
  6. Immunity. 2020 Jun 16;52(6):971-977.e3 - PubMed
  7. N Engl J Med. 2020 Sep 10;383(11):1085-1087 - PubMed
  8. MMWR Morb Mortal Wkly Rep. 2020 Nov 06;69(44):1631-1634 - PubMed
  9. Clin Infect Dis. 2020 Nov 5;71(8):1943-1946 - PubMed
  10. Nat Commun. 2020 Oct 14;11(1):5152 - PubMed
  11. PLoS Pathog. 2021 Jan 14;17(1):e1009161 - PubMed
  12. Arch Argent Pediatr. 2020 Dec;118(6):381-385 - PubMed
  13. PLoS One. 2020 Nov 3;15(11):e0241536 - PubMed

Publication Types